On Dec. 4, 2020, Eli Lilly and UnitedHealth Group announced a partnership to conduct a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, COVID-19 infected individuals. The trial evaluated the efficacy and safety of bamlanivimab versus a propensity-matched control in individuals that meet the EUA criteria.